Loading stock data…
CERT
$6.18+0.05 (+0.82%)
Market ClosedLast close May 1
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Middle East, Africa, and Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Certara, Inc. in the Healthcare sector is trading at $6.18. The stock is currently near its 52-week low of $5.19, remaining 32.5% below its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why CERT maintains its current current market pressure. The Whystock Score of 30/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.18
Potential Upside
5%
Whystock Fair Value$6.49
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus11 analysts
Buy
Mean target$8.71+41.0%
Range$6.35 – $11.00
Fundamentals
Certara, Inc., together with its subsidiaries, provides technology-driven services and software products for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the Americas, Europe, the Mi...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.02B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.62
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
0.75%
Volume
Today's trading volume
2.63M
Recent News
How The Certara (CERT) Story Is Shifting As Analysts Recut Targets And Expectations
Certara’s updated fair value estimate has shifted from US$8.99 to US$8.71, a small reset that still sits in the same broad price target zone as recent Street moves toward roughly US$8 to US$10. Those lower targets line up with more cautious research commentary, as firms weigh questions around growth visibility, execution under new leadership, and how much to pay for the stock at current levels. As you read on, you will see how these price target revisions fit into the evolving analyst...
How The Certara (CERT) Story Is Evolving As Price Targets Reset And Growth Plans Lag
Certara’s updated fair value estimate has shifted from US$9.19 to US$8.99, a modest 2.2% reset that reflects small tweaks to the underlying cash flow assumptions. This change lines up with recent research where several firms have trimmed price targets and moved to more cautious stances, while still debating the company’s long term potential versus near term execution questions. As you read on, you will see how these price target moves fit into the broader analyst narrative and what that means...
Protagonist Therapeutics (PTGX) Soars 4.7%: Is Further Upside Left in the Stock?
Protagonist Therapeutics (PTGX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.
Is Certara (CERT) Offering Opportunity After Prolonged Share Price Weakness
If you are looking at Certara and wondering whether the recent share price offers value or just more risk, you are not alone. The stock closed at US$6.65, with a 7 day return of a 5.8% decline, a 30 day return of 0.5%, and longer term returns of a 23.9% decline year to date and a 39.1% decline over 1 year, widening to a 70.3% decline over 3 years and a 78.5% decline over 5 years. These moves have played out against a backdrop of ongoing attention on Certara's position in the healthcare and...
Certara Conference: 2025 revenue hits guidance, EBITDA margin tops range as Q4 software bookings slip
Certara (NASDAQ:CERT) closed 2025 with results that Chief Financial Officer John Gallagher described as strong on revenue and profitability, while acknowledging mixed bookings trends and continued lumpiness in services demand. Speaking with analyst Luke Sergott at a company event, Gallagher said the